Arcellx Inc, a biotechnology firm focused on cell therapy innovations, has announced impressive results from its studies on ...

A new scientific trial evaluating Bavarian Nordic’s mpox vaccine in pregnant and breastfeeding women and infants is set to launch in the Democratic Republic of Congo (DRC). This research could expand ...

Johnson & Johnson has announced that the UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has approved BALVERSA (erdafitinib) for treating adults with unresectable or metastatic ...

When I first entered the clinical research industry more than 20 years ago, trials were focused mainly on recruitment goals and data collection, with less attention to the challenges faced by research ...

Alexion, AstraZeneca Rare Disease, announced that the National Institute for Health and Care Excellence (NICE) has given a positive recommendation for Voydeya (danicopan). This first-in-class, oral ...

Valneva Scotland has partnered with Team Jak, a West Lothian-headquartered charity focused on supporting children and young people with cancer. The Livingston-based vaccine producer will provide ...

There are around 55,100 new prostate cancer cases in the UK every year HBC Immunology (HBCI) has announced that an oral formulation of its lead peptide “significantly augmented” the anti-tumour ...

The London hub is home to life sciences companies including Novartis, Engitix and invoX Pharma Vivan Therapeutics has signed a new five-year lease at White City Place, a biotech hub in London home to ...

New treatment option for patients with newly diagnosed multiple myeloma The European Commission has approved the subcutaneous (SC) formulation of DARZALEX (daratumumab) in combination with bortezomib, ...

Innovative Trials has appointed Ian Keith as Finance and Business Services Director Innovative Trials has appointed Ian Keith, who has been supporting the company as a Business Consultant since the ...

Calluna Pharma AS has announced the successful completion of Phase 1 clinical trials for its lead drug candidate, CAL101, a first-in-class monoclonal antibody (mAb) targeting fibrotic and ...